BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21238998)

  • 1. Evaluation of prostate specific antigen acceleration for prostate cancer diagnosis.
    Benecchi L; Pieri AM; Pastizzaro CD; Potenzoni M
    J Urol; 2011 Mar; 185(3):821-6. PubMed ID: 21238998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal measure of PSA kinetics to identify prostate cancer.
    Benecchi L; Pieri AM; Destro Pastizzaro C; Potenzoni M
    Urology; 2008 Mar; 71(3):390-4. PubMed ID: 18342170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PSA volume quotient: an additional parameter in diagnosis of locally confined prostate cancer].
    Gottfried HW; Kleinschmidt K; Flohr P; Miller K; Hautmann R
    Urologe A; 1993 Nov; 32(6):455-9. PubMed ID: 7506850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percent free prostate specific antigen does not enhance the specificity of total prostate specific antigen for the detection of prostate cancer in Korean men 50 to 65 years old: a prospective multicenter study.
    Jeong IG; Lee KH;
    J Urol; 2008 Jan; 179(1):111-6. PubMed ID: 17997422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Usefulness of free prostate specific antigen in the detection of prostate cancer].
    Azócar G; Castillo O; Van Cauwelaert R; Cumsille MA; Campero JM; Aguirre C; Wöhler C
    Rev Med Chil; 1999 Feb; 127(2):151-7. PubMed ID: 10436694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
    Morote J; Raventós CX; Lorente JA; Lopez-Pacios MA; Encabo G; de Torres I; Andreu J
    J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
    Shao Q; Song J; Zhou ZJ; Du LD
    Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific antigen ratio: for diagnosis and assessment of aggressiveness of malignancy of prostate.
    Kapoor N; Jain R; Surange S; Bhardwaj VK; Srivastava A
    Indian J Pathol Microbiol; 2006 Apr; 49(2):178-81. PubMed ID: 16933710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
    Andriole GL; Marberger M; Roehrborn CG
    J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The usefulness of percentage of free prostate specific antigen/prostate specific antigen density in the diagnosis of prostate cancer].
    Han G; Gao JP; Cao XL; Hong BF; Tang J
    Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):379-81. PubMed ID: 16638346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early diagnosis of prostate cancer using free/total prostate-specific antigen ratio with population-based screening data].
    Zhang L; Ji G; Li X; Wang W; Gao H; Pan Y; Wang H; Masaaki K; Zhao X
    Zhonghua Nan Ke Xue; 2004 Aug; 10(8):582-5. PubMed ID: 15362518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial.
    Stopiglia RM; Ferreira U; Silva MM; Matheus WE; Denardi F; Reis LO
    J Urol; 2010 Mar; 183(3):940-4. PubMed ID: 20089269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Present-day possibilities of prostate cancer screening in patients with benign prostatic hyperplasia before and after surgical treatment].
    Pushkar' DIu; Rasner PI; Skobelev PP
    Urologiia; 2001; (6):48-54. PubMed ID: 11785083
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate-specific antigen levels and subsequent prostate cancer: potential for screening.
    Helzlsouer KJ; Newby J; Comstock GW
    Cancer Epidemiol Biomarkers Prev; 1992; 1(7):537-40. PubMed ID: 1284590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.
    Aksoy Y; Oral A; Aksoy H; Demirel A; Akcay F
    Ann Clin Lab Sci; 2003; 33(3):320-3. PubMed ID: 12956448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
    Moul JW; Sun L; Hotaling JM; Fitzsimons NJ; Polascik TJ; Robertson CN; Dahm P; Anscher MS; Mouraviev V; Pappas PA; Albala DM
    J Urol; 2007 Feb; 177(2):499-503; discussion 503-4. PubMed ID: 17222618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
    Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate specific antigen assay standardization bias could affect clinical decision making.
    Loeb S; Chan DW; Sokoll L; Kan D; Maggiore J; Mikolajczyk SD; Mondo DM; Griffin CR; Catalona WJ
    J Urol; 2008 Nov; 180(5):1959-62; discussion 1962-3. PubMed ID: 18801532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
    Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
    J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.